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Aim: To evaluate the effectiveness of L-arginine in the prevention of endothelial dysfunction, which may be a predictor of anthracy- 
cline-induced myocardial injury, in patients with acute leukemia (AL) on the background of anthracycline antibiotics low cumula­
tive doses from 100 to 200 mg/m2. M aterials and Methods: A total of 81 adult AL patients (38 males and 43 females with the age 
of 16—59 years) were studied. The patients were divided into two groups: group I (n =  34), AL patients treated with chemotherapy 
(CT) and L-arginine hydrochloride; group II (n =  47) — AL patients treated with CT only. Cardiac evaluation and endothelial 
function assessment were performed at baseline and after second CT. Electrocardiography (ECG) parameters, lipid peroxidation 
activity, antioxidant protection and NO system state were evaluated. Results: The bioelectric activity abnormalities of the myocardium 
were observed in studied patients with low cardiac risk after induction CT. In case of L-arginine administration, only minimal daily 
ECG changes were recorded. A significant difference in the lipid peroxidation and antioxidant defense system activity in patients 
of groups I and II was determined. We noticed deepening of endothelial dysfunction on the background of cytostatic therapy with 
anthracycline antibiotics compared with baseline values in patients of group II. It was found that prophylactic L-arginine increases 
superoxide dismutase level and reduces the total NO S activity due to its inducible isoform. Conclusion: The leading factor of an- 
thracycline-induced cardiotoxicity is the imbalance between free radical generation and their inactivation that leads to endothelial 
dysfunction development. L-arginine eliminates the prooxidant-antioxidant imbalance and improves the endothelial function.
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Chemotherapy (CT) with the inclusion of anthracy­
cline antibiotics (AA) is accompanied by the formation 
of systemic endothelial dysfunction, which potenti­
ates the risk of cardiovascular complications, even 
in patients with low cardiac risk. There is a systemic 
endothelial dysfunction at the onset of acute leuke­
mia (AL), which primarily creates conditions for the 
occurrence of cytostatic-induced cardiotoxic effects. 
The heart tissue injury significantly limits the effec­
tiveness of CT, taking into account the risk of acute 
coronary events development, by increasing morbidity 
and/or mortality [1].
Anthracycline-induced toxic effect on vascular 
endothelium is realized by increased oxidative stress. 
Simultaneously, tumor cells also require adequate 
functioning of the endothelium for their own growth 
and proliferation. It is interesting to note, some 
authors [2, 3] consider AA to be more toxic towards 
the endothelial than to blast cells. Thus, doxorubicin 
and other quinones cause inhibition of topoisome- 
rase II, leading to chemical and oxidative DNA dam­
age and therefore the myocardium injury. Doxorubicin
Submitted: May 3, 2017.
Correspondence: E-mail: tlymanets@gmail.com
Fax: +38 (0532) 561489;
Abbreviations used: AA -  anthracycline antibiotics; AL -  acute 
leukemia; ALL -  acute lymphoblastic leukemia; AML -  acute my­
eloid leukemia; CT -  chemotherapy; ECG -  electrocardiography; 
ECOG -  Eastern Cooperative Oncology Group scale; LPO -  lipid 
peroxidation; NO -  nitric oxide; NOS -  nitric oxide synthase;
SEs -  supraventricular extrasystoles; SOD -  superoxide dis­
mutase; TBARS -  thiobarbituric acid reactive substances.
induces production of hydrogen peroxide (H20 2), 
causing toxicity in relation to both endothelial cells 
and cardiomyocytes [4]. In the presence of oxygen the 
anthracycline semiquinones can directly transfer their 
unpaired electrons to oxygen, generating superoxide 
anion radical. If it is not balanced with antioxidants the 
lipid peroxidation (LPO) activates, followed by cardio­
myocytes’ injury [5, 6].
Endothelial cells are of great importance in the 
heart tissue functioning. The cardiomyocytes generate 
contractile force, the fibroblasts secrete extracellular 
matrix components and paracrine factors, and the 
endothelial cells are lining the coronary vessels and 
provide through the blood flow the delivery of free fatty 
acids and oxygen needed to support the high meta­
bolic needs of contractile myocytes. Furthermore, the 
endothelial cells produce glycoproteins and neuregu- 
lin 1, which binds to a receptor tyrosine kinase ErbB-4, 
which activates intracellular signaling extracellular ki­
nase 1 /2  (ERK 1 /2) and phosphatidylinositol-3-kinase 
(PI-3 K), involved in ensuring the contractile function 
of cardiomyocytes and their proliferation. Healthy en­
dothelium is very important forthe homeostasis of the 
whole cardiovascular system. Mature endothelial cells 
and their predecessors are involved in maintaining 
physiological homeostasis of cardiac tissue, including 
the regulation of vascular tone and permeability and 
thickness of the intima, vascular remodeling and an­
giogenesis processes, coagulation and fibrinolysis [7].
The reduced concentration of nitric oxide (NO) 
in the endothelium of coronary vessels is the basis 
of endothelial dysfunction, due to the deterioration
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of L-arginine bioavailability, a decrease of NO syn­
thesis or its accelerated catalysis [8]. In the present 
aspect, the NO-donor — L-arginine — is a promising 
drug for prevention of anthracycline-induced myo­
cardial injury. L-arginine is a conditionally essential 
amino acid, which is an active and multifaceted cellular 
regulator of many essential functions in the organism, 
plays antihypoxic, membrane stabilizing, antioxidant 
and detoxification actions. In the human body, it acts 
as a substrate for NO-synthase in the NO synthesis 
reaction. Also, L-arginine is able to control the release 
of NO and restore endothelial function.
Non-enzymatic pathway of L-arginine is of great in­
terest. In conditions of high oxidative stress that occurs 
during AACT, L-arginine by the reaction with H20 2 leads 
to the NO formation. Thus, L-arginine makes more 
antioxidant effect that is characterized by free radicals 
inactivation with simultaneous formation of NO, which 
significantly reduces the LPO activity and leads to en­
dothelium dependent vasodilatation [9, 10].
Considering the m echanism s of card io tox ic  
AA injury and L-arginine cardioprotective effect, in our 
view, the evaluation of its prophylactic effectiveness 
deserves special attention in patients with AL during 
induction courses of CT.
The aim of our study was to evaluate the effec­
tiveness of L-arginine in the prevention of endothe­
lial dysfunction, a predictor of anthracycline-induced 
myocardial injury in patients with ALon the background 
ofAAIowcumulativedosesfrom 100 to 200 mg/m2inthe 
CT dynamics.
MATERIALS AND METHODS
A total of 81 patients with newly diagnosed AL without 
any comorbid cardiovascular diseases were included 
in the study. The cohort consisted of 38 (46.9%) males 
and 43 (53.1%) females with the age of 16-59 years. All 
patients were hospitalized in the Hematology Depart­
ment of M.V. Sklifosovsky Poltava Regional Clinical 
Hospital. 29 (35.8%) patients were with acute lympho­
blastic leukemia (ALL) and 52 (64.2%) patients — with 
acute myeloid leukemia (AML), by ECOG l-ll. The ALL 
patients were treated with cytostatic therapy according 
to Hoelzer protocol, and AML patients — with “7+3” or 
“5+2” courses that included AA.
Depending on the treatment patients were divided 
into two groups: I (n = 34) — AL patients treated with 
CT and for anthracycline cardiotoxicity prevention 
received L-arginine hydrochloride 4.2% 100 ml intra­
venously the day before and in the days of AA infusion, 
followed by oral L-arginine aspartate 5 ml three times 
a day during one month; II (n = 47) — AL patients treat­
ed with CT without prevention of AA cardiotoxic action. 
The control group consisted of 18 healthy individuals 
(10 men and 8 women, mean age 22.5 + 2.1 years). 
The study was approved by the local ethical commit­
tee and all patients had given a written consent before 
they were included in the study.
The patients ’ condition assessment was per­
formed twice: before CT and after two induction
of remission courses in achieving AA cumulative 
dose of 100-200 mg/m2. In all patients, resting 12- 
lead electrocardiography (ECG) was performed with 
dynamic assessment of ECG parameters: heart rate, 
ORS voltage, Q-7interval, STsegmentand presence 
of repolarization changes, arrhythmias or other abnor­
malities. Daily ECG-monitoring was performed using 
ECG Holter monitoring system “CardioSens K” (KAI 
Medica, Ukraine, 2014), assessed the general cha­
racteristics of heart rate, types of cardiac arrhythmias, 
changes in ST segment and O -T  interval. The results 
were processed and evaluated using a computer pro­
gram for statistical analysis “CardioSens K” .
Simultaneously, the LPO activity was examined 
according to thiobarbituric acid reactive substances 
(TBARS) concentration. The state of antioxidant sys­
tem was assessed by superoxide dismutase (SOD) 
activity in the blood serum. NO system assessment 
was carried out by determining the stable metabolites 
of nitric oxide — nitrite anions [N 02]“ in serum through 
the formation of diazo compounds in reactions with 
sulfanilic acid, and total nitric oxide synthase (NOS) 
activity. Blood for the study was taken in the morning 
from cubital vein, patients were fasting.
These clinical and biochemical investigations were 
processed by variation statistics of Student and Fisher. 
Statistical analysis of parameters was performed 
on a personal computer using Microsoft Office Excel 
2010. Differences were considered as statistically 
significant a tp <  0.05.
RESULTS AND DISCUSSION
At baseline dyspnea during physical activity dis­
turbed 16 (47.1 %) patients of group I and 25 (53.2%) — 
of group II. Palpitation, feeling disruptions in heart work 
noted 7 (20.6%) patients of group I and 9 (19.1%) — 
of group II. The above complaints and their severity 
at the onset of AL, primarily, may be associated with 
different intensity of intoxication and anemic syn­
dromes.
During standard resting 12-lead ECG before 
starting CT in 7 (20.6%) patients of group I cardiac 
arrhythmias in the form of sinus tachycardia were 
noted, which also were recorded in 11 (24.4%) patients 
of group II. According to the results of Holter daily 
ECG-monitoring signs of tachycardia were recorded 
in 17 (50.0%) patients and single supraventricular 
extrasystoies (SEs) in 14 (41.2%) patients of group I, 
that met the increase of their physical activity. Similar 
changes were observed among patients of group II: 
tachycard ia  — in 25 (53.2% ) patien ts, SEs — 
in 19 (40.4%) patients. The changes of ST segment 
and O -T  interval in patients of both groups were not 
registered.
After standard induction CT cumulative AA dose re­
ached (179.2 ± 19.24 mg/m2) and (174.07 ± 22.13 mg/m2) 
in patients of groups I and II, respectively (p > 0.05). 
Patients of group I treated with L-arginine to prevent 
anthracycline myocardial injury, did not show any 
cardiac complaints. Increasing AA cumulative doses
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in patients of group II was accompanied by short-term 
(during 4.12 ± 1.2 days) complaints on shortness 
of breath during physical activity and palpitation 
in 12 (25.5%) patients. Reducing the intensity and 
duration of cardiac complaints in the accumulation 
of doxorubicin within 100-200 m g/m 2 compared 
with the baseline data in patients who did not receive 
prophylaxis of AA cardiotoxic action can be explained 
by decrease of intoxication and anemic syndromes 
under adequate specific and symptomatic treatment.
At standard ECG registration in patients of group I af­
ter induction phase with prophylactic L-arginine ad­
ministration the following changes were found: sinus 
tachycardia — in 6 (17.6%) patients, reduced repo­
larization processes — in 2 (5.9%) and reduced QRS 
voltage — in 1 (2.9%) patient. According to daily ECG- 
monitoring in 9 (26.5%) patients isolated SEs during 
episodes of tachycardia were detected.
According to the data of standard ECG in 16 (34.0%) 
patients in group II the presence of sinus tachycardia 
was recorded, which was accompanied by repolar­
ization abnormalities in 9 (19.1%) patients and total 
QRS decrease in 5 (10.6%) patients. However, during 
the daily ECG-monitoring in 23 (49.0%) patients with 
minimal physical activity on the background of tachy­
cardia periods the SE episodes were detected. The ST- 
segment depression and 0 - 7 prolongation in patients 
the both groups were not observed.
ECG changes registered in our study in patients 
who received low cumulative dose of AA as a part 
of induction CT without prophylactic L-arginine ad­
ministration, namely, sinus tachycardia, decreased 
repolarization processes and reduced total QRS volt­
age, are consistent with those obtained previously 
in Horacek etal. study [11].
Thus, after AL induction CT in the background 
of AA low cumulative doses the bioelectric activity ab­
normalities of the myocardium were observed in stud­
ied patients with low cardiac risk. During CT without 
prevention of anthracycline cardiotoxicity the ECG 
changes of daily monitoring were detected in 49% 
of patients. At the same time, 26.5% of group I pa­
tients, who received L-arginine, only minimal daily 
ECG changes were recorded. So, we can assume that 
AA cause progressive changes in the myocardium 
of young and middle age patients without comorbid 
cardiovascular diseases. The L-arginine administra­
tion can significantly improve the bioelectric activity 
parameters of the myocardium and minimize cardio- 
myocytes’ injury with anthracyclines.
Evaluating the LPO activity in patients of groups I and 
II before the CT revealed increased TBARS concentra­
tion in the blood serum in 1.6 times compared to al­
most healthy (p < 0.01), which indicates a high level 
production of aggressive free radicals in the AL mani­
festo. At the same time, the reduced in 2.3 times SOD 
activity was noted in serum compared to normal values 
(p < 0 .00 І) (Table). Reducing the potential antioxidant 
defense system, namely SOD activity, may be due to its 
depletion in the reaction with superoxide anion-radical.
Simultaneously with oxidative stress am . aron the in­
creased total NOS activity in 3.9 times p  < 3.001) was 
noted, which can be explained by mass' e oroduction 
of inducible NOS under the influence o* oco-inflamma- 
tory cytokines. The concentration of n ІІІ ІІ.0 a^/onsthat 
reflect the level of endothelial NO, in pat ents without 
cardiac risk factors was not significa-: . decreased, 
indicating the absence of clinically significant endo­
thelial dysfunction at the baseline.
Table. Prooxidant-antioxidant status and N0 syste- : г £ - ; ~  -  oatients 
with AL in CT dynamics
Study groups
Practically healthy 
(n = 18)
Group I before 
(n = 34) treatment 
after CT
Group II before 
(n = 47) treatment 
________after CT
TBARS, SOD,
umol/l_______ U/ml_______
8.16 ±0.51 0.94 ± 0.034 3 .2 + 1 IS
13.0 ± 1.44* 0.44 ±0.031* 2.61 ±  і  X  
10.7 ± 1.25 0.55 ± 0.021 *v 2 .9=1 I f
13.1 ± 1.42* 0.41 +0.028* 2.7 + 0.4: 
17.0 ± 1.09*^ 0.46 ± 0.031*= 2.2 = І ІЄ
NOS,
-min
:.51=0.08
13 =  0.12*
-..£ = o n te
2.4 =  0.11* 
I±2±0.1*§
Notes: significant differences (p < 0.05): ‘ between *+ = --. :  and in the
groups; vbetween indicators before and after c _ : ' r  C7 - group; 
sbetween indicators after induction C T ir ; = : e ~  r  .
The TBARS level during 3“  -  group I pa­
tients’ blood serum, what underwent prevention of an­
thracycline cardiotoxicity. has decreased the relative 
baseline level in 1.2 times (p > 0.05). In addition, the 
decrease in LPO activity1 was accompanied bya moder­
ate antioxidant protection recovery. After the second 
CT course on the background o f L-arginine admin­
istration a significant increase in 1.2 times of SOD 
activity in serum (p < 0.32 .as noted compared with 
those before treatment, bet remained significantly 
lower level of its active  comoared :o almost healthy 
(p< 0.001). In the contextoftheanthracydine-induced 
myocardial injury prevention with L-arginine in patients 
ofthe group : r a a : - a _: a significant
decrease in total NOS activity in 1 7 :  ~es was ob­
served compared with the baseline value э < 0.001), 
indicating a decrease in production of inducible NO- 
synthase. At the same time, the nitrite anion concen­
tration tended to increase in 1.1 times - the serum 
of patients of this group after induction C~ (p > 0.05). 
L-arginine administration to prevent the development 
of early anthracycline cardiotoxicity' leads to endothe­
lial function improvement and consec_.ee _. reduces 
the risk of anthracycline-inducec myocardial injury 
on the background of CT induction courses.
In comparison with the basetee .aiues, TBARS 
level significantly increased in 1 .4 : ~es ip  < 0.02) 
in patients of group II, who did not receive L-arginine, 
after the second CT course. In paralel we observed 
the moderate growth of SOD a c r . r  - the blood 
serum (0.46 ± 0.031 U/ml vs 0.41 ±  0.028 U/ml; 
p  > 0.05), indicating the preservation of low an­
tioxidant system activity and therefore a nigh risk 
of multiple organ complications r :  ug "earttissue
injury. Patients of group II after .ocuc: on C_ kept con­
sistently high activity of total NOS 2 -2  mmol/l/min), 
which was accompanied by a sign meant decrease 
of nitrites level in 1.45 times э < 0.05) compared
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with practically healthy and in 1.2 times (p > 0.05) 
compared with baseline level (see Table). Based 
on the previous experimental studies of Weinstein 
et al. [12], it is conceivable that the injuring effects 
on the endothelium are caused by the inducible iso­
form of NOS. Therefore, the above changes in total 
NOS activity with simultaneous progressive reduc­
tion of nitrites, which we obtained in this study, can 
be considered as deepening of endothelial dysfunc­
tion on the background of cytostatic therapy with AA.
Thus, in evaluating the TBARS concentration 
and SOD activity rates after induction CT in patients 
of the groups I and II, a significant difference in the 
LPO and antioxidant defense system activity was de- 
termined. It was found that prophylactic L-arginine 
adm in istra tion improves antiox idant pro tection  
by increasing the SOD activity, which leads to more 
adequate inactivation of aggressive free radicals and 
effectively corrects signs of endothelial dysfunction, 
reducing the total NOS activity due to its inducible 
isoform.
CONCLUSION
The leading fac to r of anthracycline-induced 
cardiotoxicity is the imbalance between free radical 
generation and their level of inactivation that leads 
to endothelial dysfunction development. At reach­
ing AA cum ulative dose of 100-200 m g /m 2 the 
progressive LPO activation is observed, accom ­
panied by a pronounced exhaustion of antioxidant 
protection.
L-arginine administration during the induction 
CT courses in patients with AL achieves tendency 
to e lim inate  p roox idan t-an tiox idan t im balance 
by increasing the activity of antioxidant defense 
system with simultaneous improvement of endo­
thelial function.
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